MedTrace Logo

Evaluation of an Antithrombotic Therapeutic Strategy in Pregnant Women

NCT00745212 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2280

Last updated 2017-11-09

No results posted yet for this study

Summary

The venous thromboembolism is one of the first causes of maternal mortality. Until 2003, only a few recommendations were available on the optimal use of antithrombotic therapy as a preventive measure against thromboembolism in pregnant women. In this study, we propose :

1. To gather the experts who took part in the French consensus conference and the local experts to create a score in accordance with the national and international consensus and to give some precise therapeutic strategies.
2. To evaluate the discriminant, feasible and useful character of this new score by a prospective multicentric study including 2000 pregnant women with a risk of thromboembolism or placental vascular pathology who will benefit from therapeutic strategies defined by the new score.

.

Conditions

  • Placental Vascular Pathologies
  • Venous Thromboembolism Diseases

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • Céline CHAULEUR, MD PhD · CHU de Saint-Etienne

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2012-12-31
Completion
2013-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00745212 on ClinicalTrials.gov